title: A report from the 2014 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting (November 14-19 - Boston, Massachusetts, USA).
abstract: With freezing cold temperatures outside but great excitement for new research inside Boston's Convention and Exhibition Center, clinical research on recently launched and investigational small molecular drugs and biologics as well as preclinical research with novel compounds acting on new targets that are paving the way to future developments in the therapeutic armamentarium against rheumatoid arthritis and other bone and joint diseases focused the attention of researchers and clinicians attending this year's scientific sessions of the American College of Rheumatology. The conference started with a full-blast poster session during which significant research advancements were disclosed, but parallel abstract sessions were not far behind in attendance, hooking the interest of attendees from across the world.
authors.affiliation: Thomson Reuters, Barcelona, Spain. xavier.rabasseda@thomsonreuters.com.
authors.forename: X
authors.initials: X
authors.lastname: Rabasseda
mesh_terms: D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002986:Clinical Trials as Topic; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D012216:Rheumatic Diseases / Q000188:drug therapy*; D012219:Rheumatology; D012595:Scleroderma, Systemic / Q000188:drug therapy
keywords: Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis; Systemic lupus erythematosus